Skip to main content

Month: June 2020

NOHO PARTNERS OYJ:N OSAVUOSIKATSAUS 1.1.–31.3.2020: Koronapandemia vaikutti voimakkaasti liiketoimintaympäristöön – yhtiö aloitti määrätietoiset sopeuttamistoimet

NoHo Partners OyjNOHO PARTNERS OYJ:N OSAVUOSIKATSAUS 1.1.–31.3.2020Koronapandemia vaikutti voimakkaasti liiketoimintaympäristöön – yhtiö aloitti määrätietoiset sopeuttamistoimetMaaliskuussa 2020 koronaviruspandemian aiheuttaman markkinaromahduksen johdosta konsernin liiketoiminta pysähtyi lähes täysin. Ravintolaliiketoiminnan tammi–helmikuun 2020 liikevaihto kasvoi odotusten mukaisesti noin 7,5 miljoonaa euroa viime vuoden vastaavasta jaksosta ja liikevoitto kasvoi noin 0,6 miljoonaa euroa. Ravintolaliiketoiminnan tulos supistui maaliskuussa 9,0 miljoonaa euroa, koska liikevaihto laski markkinahäiriön vuoksi viime vuoden vastaavasta kuukaudesta 10,7 miljoonaa euroa, eivätkä yhtiön käynnistämät sopeuttamistoimenpiteet ehtineet vielä vaikuttaa maaliskuun tulokseen. Yhtiö reagoi välittömästi markkinahäiriön ilmetessä aloittaen määrätietoiset...

Continue reading

LHV Group results in May 2020

In May 2020, AS LHV Group earned a net profit of EUR 2.8 million. AS LHV Pank earned EUR 2.6 million and AS LHV Varahaldus EUR 0.3 million as net profit.After an unsettled April due to the emergency situation, May was characterized by recovering business volumes and moving towards the finishing line with many important projects. The loan portfolio, deposits as well as volume of funds are all increasing. Corporate loan portfolio increased by EUR 12 million and retail loan portfolio grew by EUR 10 million. Consolidated deposits increased by EUR 159 million, including payments intermediaries deposits by EUR 116 million and retail deposits by EUR 17 million.Otherwise normal month regarding revenue and expenses was influenced by the EUR 0.3 million financial expense from the revaluation of the liquidity portfolio of the bank. Because of the...

Continue reading

LHV Groupi tulemused mais 2020

AS LHV Group teenis 2020. aasta mais 2,8 miljonit eurot puhaskasumit. AS LHV Pank teenis 2,6 miljonit eurot ja AS LHV Varahaldus 0,3 miljonit eurot puhaskasumit.Eriolukorrast tingituna heitliku aprilli järel iseloomustas maikuud LHV jaoks ärimahtude taastumine ning mitme olulise projektiga lõpusirgele jõudmine. Suurenemas on nii laenuportfell, hoiuste maht kui ka fondide maht. Ettevõtete panganduse laenuportfell kasvas 12 miljoni euro ja jaelaenude portfell 10 miljoni euro võrra. Konsolideeritud hoiused kasvasid kuuga 159 miljoni euro võrra, sh maksevahendajate hoiused 116 miljoni euro võrra ja eraisikute hoiused 17 miljoni euro võrra.Muidu tavapäraste tulude ja kuludega kuu tulemusi mõjutas ka erakorralisest panga likviidsuportfelli ümberhindlusest tekkinud 0,3 miljoni euro suurune finantskulu. Tänu väiksematele allahindlustele 2,8 miljoni...

Continue reading

Unibail-Rodamco-Westfield scores “B” and stands out as industry leader for its ESG practices in ISS 2020 rating

Paris, Amsterdam, June 9, 2020           Press releaseUnibail-Rodamco-Westfield scores “B” and stands out as industry leader for its ESG practices in ISS 2020 ratingUnibail-Rodamco-Westfield (URW) is once again recognized as a global leader on Environmental, Social and Corporate Governance (ESG), achieving a score of “B” from ISS (Institutional Shareholder Services group of companies) for its ESG practices in June 2020. This is an exceptional rating level among the real estate industry companies assessed worldwide, and the best grade ever for the Group. URW ranks in the leaders group (1st decile) and is, like in 2019, awarded the Prime status, which highlights its best-in-class approach.For the Group, this top grade is an achievement highlighting the relevance and strength of both its governance and its CSR Strategy, and a recognition...

Continue reading

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 6,181,562 shares of its common stock at a public offering price of $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 927,234 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $164.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding...

Continue reading

Replimune Announces Pricing of Upsized Public Offering

BOSTON, June 08, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share. In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 1,521,738 shares of its common stock at a purchase price of $22.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $100 million, before deducting the underwriting discounts...

Continue reading

Cequence Energy Announces Extension of Stay Period to September 8, 2020 and Scheduled Delisting From the Toronto Stock Exchange

CALGARY, Alberta, June 08, 2020 (GLOBE NEWSWIRE) — Cequence Energy Ltd. (“Cequence” or the “Company”) (TSX: CQE) announces that it has obtained an order form the Court of Queen’s Bench of Alberta (the “Court”) extending the stay of proceedings previously granted by the Court on May 29, 2020 as part of Cequence’s application under the Companies’ Creditors Arrangement Act (“CCAA”). The stay of proceedings has been extended  to September 8, 2020.The extension of the stay period will allow the Company to pursue potential strategic options and alternatives to maximize the value for its stakeholders. The Company intends to work toward developing a plan of compromise or arrangement under the CCAA to be voted on by its creditors.In addition to the Court order extending the stay period, the Company also sought and...

Continue reading

Protech Home Medical Announces Filing of Preliminary Prospectus and Concurrent Private Placements

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESCINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) — Protech Home Medical Corp. (the “Company”) (TSXV: PTQ) (OTCQX: PTQQF) is pleased to announce that it has filed the preliminary prospectus in connection with its previously announced bought deal public offering (the “Public Offering”) of units (“Units”) of the Company. In addition, the Company announces that it anticipates completing, concurrent with the Public Offering: (i) a brokered private placement of 1,750,000 Units (the “Brokered Private Placement”) conducted by a syndicate of agents (the “Agents”) led by Beacon Securities Limited (“Beacon”), as sole bookrunner, and Canaccord Genuity Corp., and (ii) a non-brokered private placement of 927,826 Units (the “Non-Brokered Private Placement”,...

Continue reading

Retrophin Announces Pricing of Public Offering of Common Stock

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) — Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin. The gross proceeds from the offering are expected to be approximately $100.8 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on June 11, 2020, subject to customary closing conditions. In addition, Retrophin has granted the underwriters for the offering a 30-day option to purchase up to an additional 975,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.Jefferies, Barclays and BofA Securities are acting as the joint book-running managers...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.